Amgen Issues Statement in Response to Revised ESA Labeling Received from the FDA Today

Amgen Issues Statement in Response to Revised ESA Labeling Received from the FDA Today

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 30, 2008--Amgen (NASDAQ: AMGN) issued the following statement in response to the receipt today of the complete response on the revised ESA labeling from the FDA.

"This label is consistent with our expectations. We will soon be communicating the revised product labeling for ESAs to both physicians and patients."

The potential impact of this revised label was factored into our updated guidance announced July 28, 2008.

CONTACT: Amgen, Thousand Oaks
Trish Hawkins, 805-447-5631 (media)
Arvind Sood, 805-447-1060 (investors)

SOURCE: Amgen

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.